Natera, Inc. (NTRA)
NASDAQ: NTRA · Real-Time Price · USD
395.66
-2.12 (-0.53%)
At close: Oct 13, 2026, 4:00 PM EDT
393.00
-2.65 (-0.67%)
After-hours: Oct 13, 2026, 7:52 PM EDT
Natera Revenue
Natera had revenue of $752.75M in the quarter ending June 30, 2026, with 37.71% growth. This brings the company's revenue in the last twelve months to $2.71B, up 37.82% year-over-year. In the year 2025, Natera had annual revenue of $2.31B with 35.90% growth. That makes Natera the 4,064th largest company in the world by revenue and 1,118th in the United States.
Revenue (ttm)
$2.71B
Revenue Growth
+37.82%
P/S Ratio
21.07
Revenue / Employee
$440,892
Employees
6,140
Market Cap
57.03B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.31B | 609.20M | 35.90% |
| Dec 31, 2024 | 1.70B | 614.34M | 56.75% |
| Dec 31, 2023 | 1.08B | 262.35M | 31.99% |
| Dec 31, 2022 | 820.22M | 194.74M | 31.13% |
| Dec 31, 2021 | 625.49M | 234.48M | 59.97% |
| Dec 31, 2020 | 391.01M | 88.68M | 29.33% |
| Dec 31, 2019 | 302.33M | 44.67M | 17.34% |
| Dec 31, 2018 | 257.65M | 48.03M | 22.91% |
| Dec 31, 2017 | 209.63M | -2.89M | -1.36% |
| Dec 31, 2016 | 212.51M | 22.16M | 11.64% |
| Dec 31, 2015 | 190.36M | 31.07M | 19.50% |
| Dec 31, 2014 | 159.29M | 104.12M | 188.72% |
| Dec 31, 2013 | 55.17M | 40.92M | 287.16% |
| Dec 31, 2012 | 14.25M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Danaher | 25.11B |
| IQVIA Holdings | 16.98B |
| Labcorp Holdings | 14.35B |
| Quest Diagnostics | 11.56B |
| Agilent Technologies | 7.37B |
| Waters | 4.64B |
| IDEXX Laboratories | 4.55B |
| Illumina | 4.49B |
NTRA News
- 16 hours ago - Natera price target raised to $480 from $340 at TD Cowen - TheFly
- 17 hours ago - Natera, Transcode to collaborate on Phase 2a trial of TTX-MC138 - TheFly
- 17 hours ago - Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer - Business Wire
- 1 day ago - Natera price target raised to $435 from $355 at Morgan Stanley - TheFly
- 4 days ago - Natera announces MCED assay granted BDD by U.S. FDA - TheFly
- 4 days ago - FDA Grants Breakthrough Device Designation for Natera's Multi-Cancer Early Detection Assay - Business Wire
- 6 days ago - Natera enrolls first patients in new Signatera-guided trial - TheFly
- 6 days ago - Natera Announces Randomized, Signatera™-Guided Interventional Study in Melanoma - Business Wire